3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
19
Carcinoma, Non-Small-Cell Lung
15
Lung Neoplasms
13
Urinary Bladder Neoplasms
11
Ovarian Neoplasms
8
Non-Muscle Invasive Bladder Neoplasms
6
Neoplasm Metastasis
5
Colorectal Neoplasms
5
Cholangiocarcinoma
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Lymphoma, Large B-Cell, Diffuse
4
Fallopian Tube Neoplasms
4
Breast Neoplasms
4
Biliary Tract Neoplasms
4
Triple Negative Breast Neoplasms
3
Nasopharyngeal Carcinoma
3
Melanoma
3
Recurrence
2
Rectal Neoplasms
2
Osteosarcoma
2
Lymphoma, Follicular
2
Gallbladder Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Transitional Cell
2
Bile Duct Neoplasms
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urologic Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
lutetium Lu 177 dotatate
1
encorafenib
1
durvalumab
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Cisplatin
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Gemcitabine
×
30 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts